Relation of Gut Microbes and L-Thyroxine Through Altered Thyroxine Metabolism in Subclinical Hypothyroidism Subjects

Zhenyu Yao, Meng Zhao, Ying Gong, Wenbin Chen, Qian Wang, Yilin Fu, Tian Guo, Jiajun Zhao, Ling Gao, Tao BoFrontiers in Cellular and Infection Microbiology 2020 · DOI

Abstract

Thyroxine metabolism is a critical component of pathogenesis research and treatment strategies for subclinical hypothyroidism (SCH). While L-thyroxine replacement therapy (LRT) is typically reserved for severe cases, evidence suggests that mild SCH patients with disordered serum lipids also benefit. However, individual responses vary significantly, particularly regarding the dosage required to stabilize thyroid-stimulating hormone (TSH) levels. This study explores the role of the gut microbiome in thyroid hormone metabolism, specifically focusing on the enterohepatic circulation where conjugated thyroxine is hydrolyzed and reused. Through 16S rDNA analysis of 117 subjects, we investigated the relationship between gut microbiota composition, serum profiles, and L-thyroxine dosage. Our findings indicate that microbial composition varies significantly based on the required L-thyroxine dose and its subsequent increments, rather than serum lipid profiles alone. Specific species associated with thyroxine metabolism were identified, suggesting that the gut microbiome acts as a metabolic reservoir influencing medication requirements and SCH progression.

Introduction

Subclinical hypothyroidism (SCH) is characterized by elevated TSH levels despite normal circulating thyroxine (T4). While L-thyroxine replacement therapy (LRT) is the standard of care, clinicians often observe wide variations in the doses needed to achieve hormonal stability. A potential explanation for this discrepancy lies in the "gut-thyroid axis." Thyroxine undergoes enterohepatic circulation: the liver conjugates T4 for excretion into the bile, and bacterial enzymes in the gut—specifically $\beta$-glucuronidases and sulfatases—deconjugate it, allowing for reabsorption. If the gut microbiome's metabolic capacity is altered, it may directly impact the systemic availability of thyroid hormones, necessitating higher exogenous doses.

Methods and Study Design

This cross-sectional study analyzed fecal samples from 117 subjects with mild SCH, some of whom were receiving LRT. The study was registered as NCT01848171. Subjects were categorized into groups based on their lipid profiles, whether they received L-thyroxine treatment, and the specific dosage required (Low, Medium, or High).

Figure 1: Flowchart illustrating the categorization of 117 subjects based on lipid profiles (A) and L-thyroxine intervention/dosage (B).

Microbial profiling was performed using 16S rDNA sequencing. Bioinformatic analysis included Principal Component Analysis (PCA) to assess beta diversity and Canonical Correspondence Analysis (CCA) to determine the influence of environmental factors like serum cholesterol and T4 levels on microbial structure.

Key Results

The study revealed that the gut microbiome is more closely linked to the dosage of L-thyroxine than to the mere presence of treatment.

Microbial Clustering by Dosage

While overall microbial richness (alpha diversity) remained relatively stable across groups, beta diversity analysis showed distinct clustering based on dosage levels. Specifically, patients in the High-dose (H) group exhibited a unique microbial signature compared to those in the Low (L) or Medium (M) groups.

Figure 2: PCA plot of gut microbiota composition at the genus level, demonstrating significant clustering and separation of subjects based on L-thyroxine dosage (H: High, M: Medium, L: Low).

Specific Taxonomic Shifts

Several bacterial genera known for their hydrolase activity—including Odoribacter, Enterococcus, Alistipes, and Ruminococcus—showed significant variations in relative abundance correlated with L-thyroxine dose. For instance, Odoribacter and Enterococcus levels were significantly higher in patients requiring larger doses. Furthermore, patients whose dosage requirements increased over a 9-month follow-up period (indicating SCH progression or decreased metabolic efficiency) had lower initial abundances of Alistipes and Anaerotruncus.

The Lipid-Thyroid Interaction

CCA results suggested a synergistic effect between serum cholesterol and L-thyroxine in shaping the gut microbiome. This correlation likely stems from the metabolic similarities between iodothyronines and bile acids, both of which undergo similar processing within the gut environment.

Discussion and Limitations

These findings suggest that the gut microbiome serves as a "second reservoir" for thyroid hormones. Differences in microbial composition may explain why some patients require higher L-thyroxine doses to maintain TSH stability. However, this study has limitations, including a relatively small sample size and the use of 16S rDNA sequencing, which identifies bacterial presence but not direct functional activity. Future research utilizing shotgun metagenomics is necessary to confirm the presence and activity of specific enzymes like $\beta$-glucuronidase. Additionally, longitudinal studies are required to establish a causal link between microbial shifts and thyroid hormone requirements.

Conclusion

The gut-thyroid axis represents a significant factor in the management of subclinical hypothyroidism. By understanding how specific microbes influence thyroxine recycling, clinicians may eventually be able to use the microbiome as a biomarker for personalizing L-thyroxine therapy and predicting disease progression.

Summary updated

Abstract

Thyroxine metabolism is an important topic of pathogenesis research and treatment schedule of subclinical hypothyroidism (SCH). L-Thyroxine replacement therapy (LRT) is usually recommended for severe SCH patients only. Our previous studies reported that disordered serum lipid of mild SCH people could also benefit from LRT. However, the benefits were different among individuals, as shown by the variations in drug dosage that required to maintain thyroid-stimulating hormone (TSH) stability. Alternative pathways, such as sulfation and glucuronidation of iodothyronine, may play a role in thyroid hormones metabolism in peripheral tissues aside from thyroid. Conjugated thyroxine can be hydrolyzed and reused in tissues including gastrointestinal tract, in which gut microbiota are one of the most attractive physiological components. On this site, the roles of gut microbiota in thyroidal metabolism should be valued. In this study, a cross-sectional study was performed by analyzing 16S rDNA of gut microbiota in mild SCH patients treated with L-thyroxine or not. Subjects were divided by serum lipid level, L-thyroxine treatment, or L-thyroxine dosage, respectively. Relationship between gut microbiome and serum profile, L-thyroxine treatment, and dose were discussed. Other metabolic disorders such as type 2 diabetes and hypertension were also taken into consideration. It turned out that microbiome varied among individuals divided by dose and the increment of L-thyroxine but not by serum lipid profile. Relative abundance of certain species that were associated with thyroxine metabolism were found varied among different L-thyroxine doses although in relatively low abundance. Moreover, serum cholesterol may perform relevance effects with L-thyroxine in shaping microbiome. Our findings suggested that the differences in L-thyroxine dosage required to maintain TSH level stability, as well as the SCH development, which was displayed by the increased L-thyroxine doses in subsequent follow-up, had relationship with gut microbial composition. The reason may due to the differences in thyroxine metabolic capacity in gut. In addition, the metabolic similarity of iodothyronines and bile acid in gut also provides possibilities for the correlation between host's thyroxine and cholesterol levels. This study was registered with ClinicalTrials.gov as number NCT01848171.
BibTeX
@inproceedings{yao2020relation,
  author = {Zhenyu Yao and Meng Zhao and Ying Gong and Wenbin Chen and Qian Wang and Yilin Fu and Tian Guo and Jiajun Zhao and Ling Gao and Tao Bo},
  title = {{Relation of Gut Microbes and L-Thyroxine Through Altered Thyroxine Metabolism in Subclinical Hypothyroidism Subjects}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2020},
  doi = {10.3389/fcimb.2020.00495},
}
Figure